Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis.

Clinical transplantation and research Pub Date : 2024-06-30 Epub Date: 2024-06-21 DOI:10.4285/ctr.24.0015

Saeed Khorramnia, Zia Navidi, Amirhossein Orandi, Mojgan Mohajeri Iravani, Amirali Orandi, Ebadallah Shiri Malekabad, Seyed Hamid Pakzad Moghadam

{"title":"Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis.","authors":"Saeed Khorramnia, Zia Navidi, Amirhossein Orandi, Mojgan Mohajeri Iravani, Amirali Orandi, Ebadallah Shiri Malekabad, Seyed Hamid Pakzad Moghadam","doi":"10.4285/ctr.24.0015","DOIUrl":null,"url":null,"abstract":"Background: Tixagevimab/cilgavimab (Tix/Cil) shows promise as a prophylactic treatment against coronavirus disease 2019 (COVID-19) in solid organ transplant recipients (SOTRs). This study was performed to assess the effectiveness of Tix/Cil for preexposure prophylaxis against COVID-19 in this population.Methods: We systematically searched the Cochrane Library, Web of Science, PubMed, and Embase databases to identify articles relevant to our study up to December 15, 2023. Comprehensive Meta-Analysis (ver. 3.0) was used for data analysis.Results: The meta-analysis included seven eligible retrospective studies, encompassing a total of 4,026 SOTRs. The analysis revealed significant differences in SOTRs who received Tix/Cil preexposure prophylaxis relative to those who did not. Specifically, these differences were observed in the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (odds ratio [OR], 0.30; 95% confidence interval [CI], 0.15-0.60), hospitalization (OR, 0.24; 95% CI, 0.08-0.70), and intensive care unit admission (OR, 0.07; 95% CI, 0.02-0.22). However, mortality rate did not differ significantly between the two groups (P=0.06).Conclusions: The evidence supporting the effectiveness of Tix/Cil as preexposure prophylaxis against SARS-CoV-2 in SOTRs is of a low to moderate level. Further high-quality research is necessary to understand its effects on this population.","PeriodicalId":519901,"journal":{"name":"Clinical transplantation and research","volume":" ","pages":"136-144"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228381/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical transplantation and research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4285/ctr.24.0015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/21 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Tixagevimab/cilgavimab (Tix/Cil) shows promise as a prophylactic treatment against coronavirus disease 2019 (COVID-19) in solid organ transplant recipients (SOTRs). This study was performed to assess the effectiveness of Tix/Cil for preexposure prophylaxis against COVID-19 in this population.

Methods: We systematically searched the Cochrane Library, Web of Science, PubMed, and Embase databases to identify articles relevant to our study up to December 15, 2023. Comprehensive Meta-Analysis (ver. 3.0) was used for data analysis.

Results: The meta-analysis included seven eligible retrospective studies, encompassing a total of 4,026 SOTRs. The analysis revealed significant differences in SOTRs who received Tix/Cil preexposure prophylaxis relative to those who did not. Specifically, these differences were observed in the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (odds ratio [OR], 0.30; 95% confidence interval [CI], 0.15-0.60), hospitalization (OR, 0.24; 95% CI, 0.08-0.70), and intensive care unit admission (OR, 0.07; 95% CI, 0.02-0.22). However, mortality rate did not differ significantly between the two groups (P=0.06).

Conclusions: The evidence supporting the effectiveness of Tix/Cil as preexposure prophylaxis against SARS-CoV-2 in SOTRs is of a low to moderate level. Further high-quality research is necessary to understand its effects on this population.

查看原文本刊更多论文

实体器官移植受者使用 Tixagevimab/cilgavimab 预防 COVID-19：系统综述和荟萃分析。

背景：Tixagevimab/cilgavimab（Tix/Cil）有望成为实体器官移植受者（SOTR）预防2019年冠状病毒病（COVID-19）的治疗药物。本研究旨在评估Tix/Cil在该人群中用于COVID-19暴露前预防的有效性：我们系统地检索了 Cochrane Library、Web of Science、PubMed 和 Embase 数据库，以确定截至 2023 年 12 月 15 日与本研究相关的文章。采用综合荟萃分析（3.0 版）进行数据分析：荟萃分析包括七项符合条件的回顾性研究，共涉及 4,026 例 SOTR。分析结果显示，接受 Tix/Cil 暴露前预防治疗的 SOTR 与未接受治疗的 SOTR 存在明显差异。具体来说，这些差异体现在严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）感染率（比值比 [OR]，0.30；95% 置信区间 [CI]，0.15-0.60）、住院率（OR，0.24；95% 置信区间 [CI]，0.08-0.70）和入住重症监护室率（OR，0.07；95% 置信区间 [CI]，0.02-0.22）上。然而，两组的死亡率并无明显差异（P=0.06）：结论：Tix/Cil作为SARS-CoV-2接触前预防药物在SOTR中的有效性证据为中低水平。有必要进一步开展高质量的研究，以了解其对这一人群的效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical transplantation and research

自引率

0.00%

发文量